Bio-Inequivalence Is Not Simply Failure To Show Bioequivalence, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will propose standards for demonstrating bio-inequivalence at the April 14 meeting of the Pharmaceutical Science Advisory Committee. Topical bioequivalence and bioequivalence of highly variable drugs will be discussed as well.